Valiant Laboratories Stock Performance
|
|
|
Valiant Laboratories Company background
Founded in: 2021
Managing director: Santosh S. Vora
Valiant Laboratories Limited was originally formed as a Partnership Firm under the name and style of M/s. Bharat Chemicals through Deed of Partnership dated October 17, 1980. The said Partnership Firm, M/s. Bharat Chemicals thereafter converted into a Public Limited Company with the name Valiant Laboratories Limited through certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies.The Company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. The Company gradually, commenced manufacturing of Paracetamol by late 1982. Paracetamol (Scientific name: Acetaminophen or parahydroxyacetanilide C8H9NO2), is one of the most commonly taken analgesic worldwide and is recommended as the firstline therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. It manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of customers.Paracetamol is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms. Paracetamol is often found combined with other drugs in many over the counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products. Presently, the Company is engaged in manufacturing and dealing in Pharmaceuticals and specility chemicals. The manufacturing facility is located at Tarapur Industrial Area, Boisar in the State of Maharashtra, with an annual installed capacity of 9,000 MTPA. Within the Manufacturing Facility located at Tarapur Industrial Area, Palghar, Maharashtra, the Company has an inhouse RD infrastructure which is equipped with analytical laboratory and infrastructure for developmental activities in existing product. The Company is promoted by Shantilal Shivji Vora, Director and Dhanvallabh Ventures LLP (DVL). In July, 2022 the Company formed its wholly owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL) to diversify the business activities.The Company has come out with a Public Issue of issuing upto 11,556,000 Equity Shares through fresh issue.
Valiant Laboratories Financial Highlights
Valiant Laboratories reported a Q1 FY 2025-26 revenue of ₹46.82 crore, down -27.6% YoY, with net profit decreased -787.5% to ₹1.82 crore. For the full year FY2025–2026, revenue reached ₹138.82 crore and profit touched at ₹-2.2 crore. As of Jun '25, Valiant Laboratories’s market capitalisation stood at ₹481.86 crores. Shareholding as of Jun '25 shows promoters holding 74.9%, with FIIs at 0.6%, DIIs at 24%, and public at %.
As of 20 Aug, 2025, Valiant Laboratories share price is ₹88.6. The stock opened at ₹88.2 and had closed at ₹88.7 the previous day. During today’s trading session, Valiant Laboratories share price moved between ₹88.20 and ₹89.88, with an average price for the day of ₹89.04. Over the last 52 weeks, the stock has recorded a low of ₹69.84 and a high of ₹123.98. In terms of performance, Valiant Laboratories share price has increased by 1.7% over the past six months and has declined by 10.47% over the last year.
Valiant Laboratories Fundamental
Market Cap (in crs)
481.86
Face Value
10
Turnover (in lacs)
6.93
Key Metrics
Qtr Change %
28.54% Fall from 52W High
-8.7
Dividend yield 1yr %
0
Valiant Laboratories Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Valiant Laboratories Quarterly Revenue
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
46.82 Cr | 57.79 Cr | 35.23 Cr | 21.48 Cr | 18.88 Cr |
Valiant Laboratories Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|
138.82 Cr | 191.74 Cr | 338.77 Cr |
Valiant Laboratories Quarterly Net Profit/Loss
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
1.82 Cr | 0.7 Cr | 2.35 Cr | -4.74 Cr | -0.51 Cr |
Valiant Laboratories Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|
-2.2 Cr | 0.32 Cr | 29 Cr |
Valiant Laboratories Result Highlights
Result Summary
-
Valiant Laboratories Ltd reported a 43.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 118.8%.
-
Its expenses for the quarter were up by 26.2% QoQ and 106.0% YoY.
-
The net profit decreased 246.8% QoQ and decreased 456.9% YoY.
-
The earnings per share (EPS) of Valiant Laboratories Ltd stood at 0.4 during Q1 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Valiant Laboratories Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
88.50
Current Price
5Day EMA
89.40
10Day EMA
90.20
12Day EMA
90.50
20Day EMA
92.40
26Day EMA
93.60
50Day EMA
95.80
100Day EMA
96.50
200Day EMA
100.90
5Day SMA
89.40
10Day SMA
90.20
20Day SMA
91.20
30Day SMA
95.90
50Day SMA
100.00
100Day SMA
95.60
150Day SMA
93.30
200Day SMA
96.60
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 18759 Rs | 28285 Rs |
Week Rs | 50652 Rs | 77280 Rs |
Month Rs | 53192 Rs | 85425 Rs |
Resistance & Support
89.08
Pivot
Resistance
First Resistance
90.04
Second Resistance
91.37
Third Resistance
92.33
Support
First Support
87.75
Second support
86.79
Third Support
85.46
Relative Strength Index
41.55
Money Flow Index
61.48
MACD
-3
MACD Signal
-3.16
Average True Range
5.03
Average Directional Index
11.72
Rate of Change (21)
-13.69
Rate of Change (125)
-3.73
Valiant Laboratories Peer comparison
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
820.75 | 461.40 | 762.6 | 1753.95 | 808.05 | 1.03% | -12.37% | -9.61% | -34.05% | 53.53% | 0.62% | 73.56 | 40.64 | 1.18 | |
485.00 | 886.1 | 1410 | 1,098.95 | -3.47% | -14.65% | 8.38% | 14.44% | 87.57% | 1.64% | 14.95 | 40.64 | 2.82 | ||
505.00 | 612.45 | 250 | 625 | 509.00 | -2.77% | -14.03% | 53.38% | 60.08% | 595.41% | 0.00% | 0.00 | 40.64 | 24.38 | |
149.40 | 477.42 | 126.85 | 216.45 | 152.25 | -0.53% | -3.31% | -23.99% | -16.73% | 220.19% | 0.66% | 14.60 | 46.20 | 3.93 | |
359.70 | 474.50 | 342 | 630 | 349.85 | 4.05% | -11.46% | -31.50% | -12.40% | -58.03% | 0.27% | 53.73 | 40.64 | 1.81 | |
500.21 | 635 | 1143 | 1,059.40 | 2.06% | 15.89% | 54.37% | 35.12% | 10.80% | 0.07% | 21.34 | 40.64 | 3.54 |
Valiant Laboratories Share Price FAQs
What is Share Price of Valiant Laboratories ?
Valiant Laboratories share price is ₹88.50 in NSE and ₹88.60 in BSE as on 20/8/2025.
How has Valiant Laboratories shares performed in the past ?
Valiant Laboratories share price in the past 1-year return was -11.82. The Valiant Laboratories share hit a 1-year low of Rs. 69.84 and a 1-year high of Rs. 123.98.
What is the market cap of Valiant Laboratories ?
The market cap of Valiant Laboratories is Rs. 481.86 Cr. as of 20/8/2025.
What is the current P/E ratio of Valiant Laboratories ?
The PE ratios of Valiant Laboratories is 0 as of 20/8/2025.
What is the current PB ratio of Valiant Laboratories ?
The PB ratios of Valiant Laboratories is 1.52 as of 20/8/2025
How to buy Valiant Laboratories shares?
You can easily buy Valiant Laboratories shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Valiant Laboratories ?
The 52-week high and low of Valiant Laboratories share price is ₹123.98 and ₹69.84 as of 20/8/2025.
What is the EPS of Valiant Laboratories ?
The earnings per share (EPS) of Valiant Laboratories stood at 0.4 during Q1 FY 2025-26.
Please be aware that Valiant Laboratories stock prices are subject to continuous fluctuations due to various factors.
Open Demat Account